AAP News Vol. 15 No. 2 February 1999, p. 10
© 1999 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welch, M. J.
Right arrow Search for Related Content

 Previous Article  |  Next Article 

Be vigilant, but don't let 'steroid phobia' hinder asthma therapy

Michael J. Welch M.D., FAAP

Most pediatricians have heard about a recent decision by the Food and Drug Administration (FDA) to include new labeling language alerting health providers that use of inhaled cortico-steroids in children may reduce their growth rate. This decision and the new language resulted from a July 1998 meeting of the FDA's Pulmonary and Allergy Drugs and Metabolic and Endocrine Drugs Advisory Committees. At the meeting, I presented the AAP Section on Allergy and Immunology's opinion. The section is the largest group of pediatric allergists in the country and represents specialists in pediatric respiratory diseases who have a major interest in this issue.